Tous Actualités
Suivre
Abonner Unilabs SA

Unilabs SA

Neufassung: Unilabs reaches milestones in the year ended May 31, 2004

Un document

Geneva (ots)

Hinweis: Ein PDF-File mit einer Tabelle der Zahlen finden Sie  
            unter: http://www.newsaktuell.ch/d/story.htx?nr=100479695
- Revenues of CHF 251.4 million, up 4.1% 
- EBITDA of CHF 44.6 million, up 0.7%
- Earnings before taxes CHF 19.8 million, up 19% 
- Net income CHF 11.8 million, up 4.4%
- Stockholders' equity CHF 104.3 million, up 20.4%
- The Board of Directors will propose a 13.5% dividend increase to
  CHF 0.85 per bearer share
For the fiscal year 2003/2004, which ended on 31
May 2004, Unilabs (SWX: ULB) achieved revenues of CHF 251.4 million,
up 4.1% compared to the prior financial year. At constant exchange
rates, revenues grew by 2.2%. Revenues increased by 0.8% in
Switzerland, while internal growth in local currency increased by
12.2% in Spain and 4.5% in France. This positive performance in the
company's three largest markets, allowed Unilabs to exceed its own
guidance of 3% Group revenue growth for the fiscal year ended May 31,
2004. It also reflects a more dynamic market environment that should
allow Unilabs to accelerate revenue growth in fiscal 2004/2005 and
take advantage of new market opportunities through select
acquisitions.
Earnings before interest, taxes, depreciation and amortisation
(EBITDA) grew by 0.7% to reach CHF 44.6 million. During the period,
the Group incurred non-capitalized costs for project development
amounting to CHF 1.2 million, representing 2.7% of the prior year's
EBITDA.
Operating profit (EBIT) reached CHF 27.5 million, compared with
CHF 26.8 million, an increase of 2.5% compared to the prior year.
In connection with a swap contract, which purports to protect the
company against an increase in interest rates, in accordance with
accounting rule IAS 39, an amount of CHF 1.6 million was written back
to profit out of the previously-established provisions of CHF 4.9
million. As indicated previously, the balance of such provisions at
May 31, 2004 (CHF 3.3 million), will be written back to profit at the
latest upon termination of the contract in 2007.
Earnings before taxes increased significantly by 19.0% to CHF 19.8
million, compared with CHF 16.7 million in the previous financial
year.
Income tax provisions having increased to CHF 7.3 million as
compared to CHF 4.6 million, net income amounted to CHF 11.8 million
(or CHF 1.23 per bearer share), compared with  CHF 11.3 million (or
CHF 1.18 per bearer share) in the previous financial year.
Net income adjusted for the effect of goodwill amortisation
charges was CHF 20.7 million (or CHF 2.17 per bearer share), as
compared to CHF 19.8 million (or CHF 2.07 per bearer share) in the
previous financial year.
Strong balance sheet and cash position At 31 May 2004,
stockholders' equity grew to CHF 104.3 million versus CHF 86.6
million the previous year, an increase of 20.4%.
Free cash flow increased substantially by 19.9% to CHF 17.7
million from CHF 14.8 million in the fiscal year 2003/2004.
During the year ended May 31, 2004, Unilabs: 
- Consolidated its market share in Switzerland, Spain and France 
- Devoted substantial resources to the development of new tests and  
  to the improvement of its laboratory management systems 
- Pursued its profit improvement program in our major labs 
- Devoted significant time to the identification and review of 
  acquisition targets 
- Renewed and secured new credit lines now totalling CHF 94.0 
  million, which, compounded with the Group's current liquidity, make
a total of over CHF 50 million currently available for 
  acquisitions.
Increased dividend
At the Annual Shareholders' meeting in November 2004, the Board of
Directors will propose a dividend of CHF 0.85 per bearer share versus
CHF 0.75 the previous year, an increase of 13.5%.
Outlook
For the current fiscal year, ending May 31, 2005, Unilabs expects
an organic Group revenue growth of 4.5% in local currencies.
Conference call
Today, Unilabs will hold an investor and analyst meeting in Zurich
at 2:00 p.m. CET to discuss the financial results for the full fiscal
year. This event will be relayed live through a conference call. To
participate in the conference call, dial: +41 91 610 5600 (Europe and
Switzerland), +44 20 7107 06 11 ( UK), +1 866 291 41 66 (US). Digital
playback is available for 48 hours after the conference starting at 5
p.m. until 23 September 5 p.m., dial: +41 91 612 4330 (Europe); +44
20 866 4300 (UK); +1 412 317 0088 (US/Canada); Conference ID: 204#.
In order to view the slide presentation, a link to the presentation
will be provided immediately prior to the event on www.unilabs.ch.
Please note that sound will only be provided through the telephone
conference.
About Unilabs
The Unilabs Group (SWX: ULB) is the European leader of clinical
testing laboratories. With 40 laboratories and over 1500 employees
operating in 5 countries, Unilabs tests over 3 million samples per
year using more than 1500 different tests. Unilabs' clinical testing
services are used by over 60 public and private hospitals in France,
Spain and Switzerland. Unilabs has been listed on the SWX Swiss Stock
Exchange since 1997.

Kontakt:

Edgard Zwirn
Executive Chairman
Tel. +41/22/909'77'77
Internet: http://www.unilabs.ch

Plus de actualités: Unilabs SA
Plus de actualités: Unilabs SA
  • 20.07.2004 – 08:17

    Unilabs unterzeichnet eine neue Vereinbarung für Krankenhauslabordienste

    Genf (ots) - Das Labor Unilabs aus Lugano (Tessin) hat eine Vereinbarung mit zwei Krankenhäusern in der Nähe von Lugano unterzeichnet. Die Kliniken betreiben insgesamt 150 Betten zur stationären Behandlung von rund 6,500 Patienten sowie 32,000 ambulanten Versorgungen jährlich. Der Vertrag, der mit sofortiger Wirkung in Kraft tritt, bezieht sich auf einen ...

  • 08.07.2004 – 07:00

    Unilabs verstärkt seine Position in der Schweiz und in Spanien

    Genf (ots) - Unilabs gibt die Unterzeichnung einer Vereinbarung bekannt, die zum 1. August 2004 in Kraft tritt und den Kauf eines Anatomopathologielabors beinhaltet. Dieses Labor liegt in einer Schweizer Stadt, in der Unilabs bereits ein Labor mit dem gleichen Tätigkeitsbereich betreibt. Der Jahresumsatz beträgt rund CHF 2 Millionen. Unilabs hat darüber hinaus auch seine Position in Spanien verstärken können, ...

  • 24.06.2004 – 18:12

    Unilabs verstärkt seine Position bei den Krankenhäusern der Riviera des Kantons Waadt

    Genf (ots) - Die Krankenhäuser der Riviera des Kantons Waadt (Hôpital de Montreux und Hôpital du Samaritain in Vevey) haben Ihre Partnerschaft mit Unilabs bis zum Jahr 2011 verlängert. Mit dem Hôpital de la Providence in Vevey kommt ein weiterer Partner hinzu. Dieser Abschluss ist Zeichen einer ausgezeichneten Zusammenarbeit, die im Jahr 2000 mit dem Hôpital ...